Stock NGM NGM BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News NGM Biopharmaceuticals, Inc.

Equities

NGM

US62921N1054

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-04 pm EDT 		5-day change 1st Jan Change
1.54 USD -1.28% Intraday chart for NGM Biopharmaceuticals, Inc. 0.00% +79.28%
Apr. 05 NGM Biopharmaceuticals, Inc.(NasdaqGM:NGM) dropped from NASDAQ Composite Index CI
Apr. 05 The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NGM Bio Announces Closing of Tender Offer
GL
NGM Biopharmaceuticals, Inc.(NasdaqGM:NGM) dropped from NASDAQ Composite Index
CI
The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders.
CI
NGM Biopharmaceuticals, Inc.(NasdaqGS:NGM) dropped from S&P Global BMI Index
CI
NGM Biopharmaceuticals, Inc.(NasdaqGS:NGM) dropped from S&P TMI Index
CI
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
GL
North American Morning Briefing : Investors -2-
DJ
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
BU
North American Morning Briefing : Stock Futures -2-
DJ
Raymond James Downgrades NGM Biopharmaceuticals to Market Perform From Outperform
MT
NGM Biopharmaceuticals: Q4 Earnings Snapshot
AQ
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
North American Morning Briefing : Fed's Preferred -2-
DJ
B. Riley Lowers NGM Biopharmaceuticals' PT to $1.55 From $3.50 on Heels of Announced Sale Agreement With Affiliates of The Column Group, Keeps Buy Rating
MT
TD Cowen Downgrades NGM Biopharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $1.55 From $4
MT
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
BU
Sector Update: Health Care Stocks Ease Late Afternoon
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NGM Stock
  4. News NGM Biopharmaceuticals, Inc.